Navigation Links
Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/26/2008

fic T-cell responses. These findings verify the company's predicted mechanism-of-action of HspE7 as demonstrated by early preclinical models and support the compound's potential to treat HPV-16 induced CIN. HPV-16 is the most common subtype of the HPV virus and is responsible for a significant percentage of cases of CIN.

"We are very encouraged with the interim immunological results from our Phase 1 HspE7 trial as they demonstrate the anticipated immune response improvement from cohort 1 to cohort 2. We believe that these results may correlate to the activity of the drug in future clinical trials," said Gregory M. McKee, president and chief executive officer at Nventa. "We look forward to reviewing the immunological data from the remaining two cohorts of this study to determine if yet higher doses of HspE7 will improve the drug's immunological activity."

The company recently announced positive safety and tolerability findings from cohort 3 in this Phase 1 study, as well as the completion of enrollment and initiation of dosing for the study's fourth and final cohort. Safety and tolerability results from cohort 4 are expected in mid-April. In addition to safety findings, immunological samples for the study's third and fourth cohorts are presently being collected and evaluated, and such findings will be released in the next several months.

Nventa is currently working with the FDA to finalize trial design for the company's Phase 2 clinical study for HspE7, and expects to initiate this trial in patients in CIN in mid-2008. In addition to CIN, Nventa is currently evaluating HspE7 as a potential treatment for a broad range of HPV-related pre-cancerous and cancerous diseases, and has a platform to generate other compounds that may treat a variety of other viral associated diseases.

About Cervical Intraepithelial Neoplasia (CIN)

CIN, also known as cervical dysplasia, is characterized by the presence in the cervix of abnormal cells that prec
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
3. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
4. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
5. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
6. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
7. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
8. Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
9. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014  World Hemp Oil, ... low THC, announces they are now offering legal, organic ... Charlotte,s Web type strains grown in medical marijuana states. ... neurological disorders, such as Parkinson,s, MS, and spinal cord ... laws to pass, because imported CBD Oil Is legal ...
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... -- Market research firm Kalorama information says that 2014 will ... the medical device industry.  The firm thinks the $360 ... 3% growth this year, which led firms to look ... and entrance by acquisition into new competitive zones.  The ... The Global Market for Medical Devices, 5 th ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2
(Date:11/22/2014)... 23, 2014 Today, Dylan Queen, a ... collection of wedding dresses; the business offers a wide ... accessories for ladies worldwide, allowing them to create multiple ... the company, this new collection of chic wedding dresses ... they are offered at discounted rates now. Dylan Queen ...
(Date:11/22/2014)... Discount-Dress.com is an important company ... is to increase the company’s online market share by a ... of bridesmaid dresses and announced a bridesmaid dress promotion for ... Dec. 30, 2014. All the dresses from this company are ... In fact, Discount-Dress.com is very good at manufacturing wedding dresses. ...
(Date:11/22/2014)... November 22, 2014 "My friend went ... caused by the machine," said an inventor from Cambria ... to go back a second time because the first ... , She developed the patent-pending MAMO EASY to offer ... The design saves the patient from the pain normally ...
(Date:11/22/2014)... The wide variety and complexity of foods served at ... food allergies, an expert warns. "Every person is ... allergies that it can be really difficult to avoid ... of allergy and clinical immunology at Wake Forest Baptist ... "If you know you have food allergies, caution should ...
(Date:11/22/2014)... month has been a historical time for Angeldress.co.uk, an excellent ... from some renowned review websites. Recently, the company has added ... selection of wonderful sexy wedding dresses to its website. At ... up to an 80% discount on any order over GBP ... suitable dress at Angeldress.co.uk, which has garnered a hard core ...
Breaking Medicine News(10 mins):Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2
... , , DENVER, Sept. 15 ... of kidney care services for those diagnosed with chronic kidney disease ... the End Stage Renal Disease (ESRD) Network,s patient quality improvement goal. ... in Virginia by promoting increased use of fistulas, thereby minimizing the ...
... found 138 sites that sold them illegally, without a prescription ... on their own that they need antibiotics can easily find ... benefit of a prescription, new research shows. , The practice ... an overuse of antibiotics that is known to create resistant ...
... , , , , ... ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery products, ... Life Sciences Conference at the Grand Hyatt Hotel in New York. ... at 4:30 p.m. Eastern Time on Tuesday, September 22, 2009. , ...
... , , , PROVIDENCE, ... are invited to step forward on October 4, 2009 at ... "The Walk: Hasbro Children,s Hospital." Patients, families, hospital staff ... money to support patient care and cutting-edge pediatric research in ...
... , , , ... Inc. (Pink Sheets: ASFX) (the Company) today announced the appointment ... as Senior Vice President and Director of Business Development of ... of the intellectual property formerly owned by Safeguard, which produces ...
... , , , WASHINGTON, Sept. ... a forum held by the House Democratic Steering and Policy Committee ... are the Speaker,s remarks: , , "Good morning. ... we are closer than ever before in history to passing health ...
Cached Medicine News:Health News:New Data Shows DaVita Facilities Lead Virginia in Improving Kidney Patient Care 2Health News:Antibiotics Bought Easily on the Internet 2Health News:Antibiotics Bought Easily on the Internet 3Health News:ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 2Health News:Hasbro Children's Hospital Kicks Off Inaugural Fundraising Walk 2Health News:Hasbro Children's Hospital Kicks Off Inaugural Fundraising Walk 3Health News:American Scientific Resources, Inc. Welcomes Jason Roth 2Health News:Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 2Health News:Pelosi Remarks at Democratic Steering and Policy Committee Forum on Health Insurance Reform 3
... has been developing diverse medical ... years. Our medical-surgical products have ... innovation, quality and customer satisfaction. ... the Labtron® line of diagnostic ...
... Nebulizers deliver particulate humidity in the 3 ... secretion patients. For your convenience, Thera-Mist® nebulizers ... of sterile water., ,The P30000N, for ... 20-50% with a total flow range of ...
... can be held at angles up to 45° ... in spill column, finger grooves for a non-slip ... 7 feet of regular oxygen tubing. The ... size and sustain optimum mist concentration at every ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
Medicine Products: